Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 12/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7885028 | 0.89 | MAPK8 (0.36) | MAPK8MAPK10BRAF | |
| SCHEMBL7873261 | 0.88 | MAPK8 (0.32) | MAPK8MAPK10BRAF | |
| SCHEMBL7873918 | 0.87 | MAPK8 (0.32) | MAPK8MAPK10BRAF | |
| SCHEMBL7881278 | 0.87 | PTPN11 (0.34) | PTPN11BRAFCYP3A4 | |
| SCHEMBL7877775 | 0.86 | MET (0.37) | PTPN11BRAFRAF1 | |
| SCHEMBL7881828 | 0.86 | CLK1 (0.31) | MAPK8MAPK10 | |
| SCHEMBL7880924 | 0.85 | FFAR1 (0.36) | BRAFMAPTRAF1 | |
| SCHEMBL7881386 | 0.84 | TLR7 (0.36) | BRAF | |
| SCHEMBL7882116 | 0.84 | BRAF (0.35) | BRAFCYP3A4RAF1 | |
| SCHEMBL7882129 | 0.84 | ICAM1 (0.37) | BRAFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |